Can-Fite submits pediatric plan to FDA for Piclidenoson in psoriasis treatment
Biotech leader Can-Fite BioPharma, known for its advances in oncology, inflammatory, and liver diseases, has taken a significant step forward with its announcement today of ... Read More
Biocon Biologics signs licensing deal for two biosimilars with Yoshindo
Biocon Ltd. said that its subsidiary Biocon Biologics has signed an out-licensing agreement with Japanese pharma company Yoshindo Inc. for commercializing a couple of its ... Read More
Lupin secures Health Canada approval for Enbrel biosimilar – Rymti
Lupin Limited has secured approval from Health Canada for Rymti, the company’s biosimilar to Enbrel (etanercept), an inhibitor of tumour necrosis factor (TNF). Rymti is ... Read More
Strides Pharma gets FDA approval for Cyclosporine Softgel Capsules
Strides Pharma Science said that its stepdown fully-owned subsidiary, Strides Pharma Global Pte. Limited, Singapore, has secured approval from the US Food and Drug Administration ... Read More
Glenmark gets FDA nod for generic of psoriasis medication Enstilar Foam
Glenmark Pharmaceuticals has secured tentative approval from the US Food and Drug Administration (FDA) for Calcipotriene and Betamethasone Dipropionate Foam, 0.005%|0.064%. The product is the ... Read More
Mylan launches Hulio, a biosimilar to Humira, across major European markets
Mylan has officially launched Hulio, its biosimilar to AbbVie’s Humira (adalimumab), across major European markets. This launch follows the European Commission's recent approval of Hulio ... Read More
Boehringer Ingelheim’s Cyltezo achieves clinical equivalence to Humira in Phase 3 psoriasis trial
German pharmaceutical giant Boehringer Ingelheim has announced a significant milestone in the treatment of moderate-to-severe chronic plaque psoriasis. Their drug, Cyltezo, a biosimilar to AbbVie's ... Read More